Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. reports developments in hemp-derived cannabinoid consumer products, including the cbdMD, Paw CBD, Bluebird Botanicals and Herbal Oasis brands.
Company news focuses on CBD product categories, THC-infused social seltzer distribution, clinical and regulatory science initiatives, acquisitions, financial results, liquidity, balance-sheet actions and exchange-listing compliance.
cbdMD (YCBD) entered a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea, through an assignment for the benefit of creditors process, subject to court approval and customary closing conditions.
The companies report that combined unaudited trailing twelve‑month revenue ending June 2026 is approximately $30 million, which would be about 40% higher than cbdMD’s standalone revenue for the same period. The incremental revenue is expected to provide positive contribution after transaction and integration costs, although the combined figure is illustrative and not guidance.
The deal is intended to give Twinlab’s brands a stable home and an orderly path for legacy obligations, keeping products available to customers, retailers, and distribution partners. cbdMD expects the acquisition to reduce its revenue concentration in hemp and mitigate risks from the evolving hemp regulatory environment while expanding into supplements, sports nutrition, beauty, weight management, longevity, and broader consumer wellness. Twinlab adds a long‑standing presence across vitamins, minerals, active lifestyle and performance nutrition, including access to 50,000 retail outlets such as Vitamin Shop and GNC and a strong Amazon presence.
cbdMD (NYSE American: YCBD) reported third fiscal quarter 2026 net sales of $5.6 million, up 20% year-over-year, driven by a 61% increase in wholesale net sales, expanding Oasis beverage distribution, and the first full-quarter contribution of over $0.5 million from Bluebird Botanicals.
Direct-to-consumer sales were $3.9 million (70% of revenue), up about 9%, while wholesale reached $1.7 million (30% of revenue). Gross margin declined to from 61.5%, and loss from operations widened to about $1.13 million. However, non-GAAP Adjusted EBITDA loss improved to approximately $508,000. Net loss attributable to common shareholders was about $1.2 million, or $0.11 per share, versus $0.21 per share a year earlier.
For the first nine months of fiscal 2026, net sales rose 12% to $16.2 million and net loss attributable to common shareholders improved to about $2.4 million. According to cbdMD, cost-reduction actions initiated in July target $100,000–$150,000 in monthly savings as the company prepares for pending U.S. hemp regulations.
cbdMD (NYSE American: YCBD) will host a conference call on Thursday, August 13, 2026 at 4:20 p.m. Eastern Time to discuss its June 30, 2026 third quarter financial results and business progress. Investors can join via phone at 888-880-3330 or through a webcast with replay access available until August 13, 2027 at https://app.webinar.net/w4b2GxXG7Kv.
cbdMD (NYSE American: YCBD) reports that the Senate Appropriations Committee’s August 2 continuing resolution proposal would extend current federal rules for most naturally derived hemp products, including full-spectrum CBD, from the planned November 12 restriction date to December 11.
The draft bill would still allow restrictions on certain synthetic cannabinoids not naturally produced by the Cannabis sativa L. plant to proceed on November 12. cbdMD believes its core naturally derived, full-spectrum CBD product portfolio fits within the category intended for protection. The company emphasizes that the Senate language is not yet law, as the House version lacks these hemp provisions and final approval by both chambers and the President is required.
cbdMD (NYSE American: YCBD) announced its support for the bipartisan Lawful Hemp Protection Act introduced on July 21, 2026 by Reps. Andy Barr and Angie Craig. The bill seeks a long-term federal framework for hemp-derived products and would repeal a November 12, 2026 narrowing of the federal hemp definition under Section 781 of the FY 2026 appropriations law.
The proposed act would place hemp-derived products under FDA oversight, require third-party testing and accurate labeling, set 21-and-over age limits, mandate domestic sourcing, and restrict synthetic intoxicating cannabinoids. cbdMD also backs the Administration and Office of Management and Budget’s calls to revise the hemp definition through budget legislation.
cbdMD (NYSE American: YCBD) announced that its Oasis line of hemp-derived beverages is now available across South Carolina through a new distribution agreement with Morales Beverage Group, a statewide alcohol distributor. The deal places Oasis products on liquor store shelves, including at Frugal MacDoogal.
The rollout covers the full Oasis portfolio and highlights the new zero-proof, spirit-style Mixer, positioned for cocktails and mixed drinks. According to cbdMD, placing Oasis within established liquor retail channels supports its strategy to reach adult consumers in familiar environments and expand hemp-derived beverage accessibility over time.
cbdMD (NYSE American: YCBD), through its Bluebird Botanicals brand, announced an official partnership with Denver Audubon to support bird conservation in Colorado. The collaboration aligns with Bluebird’s Colorado roots and focus on nature, transparency, and environmental stewardship.
Through the “Buy Bluebird, Save Bluebirds” campaign, Bluebird will contribute 1% of profits from its product sales over three summer months to Denver Audubon’s conservation and education initiatives, including the Colorado Bluebird Project. cbdMD is continuing to invest in Bluebird by reinforcing its historic brand identity and customer relationships rather than repositioning the brand.
cbdMD (NYSE American: YCBD) announced completion of a self-affirmed GRAS determination for its proprietary broad spectrum CBD. An independent toxicologist panel concluded daily intake of up to 200 mg CBD is supported as safe for healthy adults, based on cbdMD-sponsored preclinical, clinical, and peer-reviewed studies in humans, animals, and companion animals.
This safety dossier may help guide product development, healthcare use, and consumer confidence.
cbdMD (NYSE American: YCBD) launched Oasis Mixer, a hemp-derived, zero-proof THC spirit under its Herbal Oasis brand. The quad-filtered, oil-free mixer is translucent, designed to avoid cloudiness, and offered in Citrus and Unflavored. Each bottle has 10mg THC per serving, 170mg total, zero calories, sugar, and carbs, plus a resealable child-resistant cap. Initial production was over-subscribed by distributors, with availability in TN, FL, TX, SC and select NC markets, subject to state laws.
cbdMD (NYSE American: YCBD) welcomed the White House request that Congress ensure fair treatment of hemp-derived products under federal law. The Administration supports hemp reform, preservation of access to appropriate full-spectrum CBD, and a responsible federal framework or extended implementation timeline, aligning with cbdMD's focus on compliant, science-backed products.